nature portfolio

NCOMMS-22-43801A Yoshikazu Kawai, Corresponding author(s): Jeff Errington

Last updated by author(s): May 29, 2023

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

~				
Ç.	tat	tic:	tıc	C

n/a	Cor	nfirmed
	x	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	x	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
X		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
×		A description of all covariates tested
×		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	×	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
x		For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
x		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
×		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
×		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

No software was used for data collection.

Data analysis

All data was analyzed as stated in the manuscript. Microscopic images were analyzed using MetaMorph software (version 7.7, Molecular Devices) and FIJI (version 2.9.0/1.53t). The concentrations of UDP-GlcNAc were determined using Agilent MassHunter Quantitative Analysis 10.2 software. GraphPadPrism software (version 9.3.1) was used for SOD activity assay.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our $\underline{\text{policy}}$

All data that generated in this study are provided in the main manuscript/Supplementary information/Source Data file.

Research involving human participants, their data, or biological material Policy information about studies with human participants or human data. See also policy information about sex, gender (identity/presentation).

and sexual orientation		thnicity and racism.		
Reporting on sex and	d gender	N/A (No human participants or human data in this study)		
Reporting on race, ethnicity, or other socially relevant groupings		N/A		
Population characteristics		N/A		
Recruitment		N/A		
Ethics oversight		N/A		
Note that full informati	ion on the appro	oval of the study protocol must also be provided in the manuscript.		
Field-spe	cific ro	norting		
		s the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
Life sciences		ehavioural & social sciences		
or a reference copy or an	e document with	insections, see interesting determination in reporting saminary nations.		
Life scien	ces stu	udy design		
All studies must disc	lose on these	points even when the disclosure is negative.		
		al methods were used to predetermine sample size. The sample size for experiments was based on prior experiments of a similar experience and knowledge on expected biological variability, as well as accuracy of the experimental methods.		
Data exclusions	No data were e	ccluded.		
Replication	Experiments we	ere repeated at least three times and the results were consistent.		
Randomization	No experimental groups were allocated in this study.			
	Since the exper reproducible.	the experimental groups were not allocated, blinding was not relevant in this study. The results were also quantitative and readily ducible.		
Renorting	for sr	pecific materials, systems and methods		
		about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material,		
system or method liste	ed is relevant to	your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.		
Materials & expe	erimental s	ystems Methods		
n/a Involved in the study n/a Involved in the study		n/a Involved in the study		
X Antibodies		ChIP-seq		
E ukaryotic ce	Eukaryotic cell lines			
Palaeontology and archaeology MRI-based neuroimaging				
Animals and other organisms				
Clinical data				
Dual use research of concern Plants				